ESMO Congress 2021
![CheckMate 649_ESMO 2021](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/checkmate-649_esmo-2021/9261621-1-eng-GB/checkmate-649_esmo-2021_i770.jpg)
Upper GI tumours: survival benefits with PD-1 inhibitors plus chemotherapy, but not nivolumab plus ipilimumab
Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours
![The paradigm shift led by CDK4/6 inhibitors in breast cancer](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2021/all-articles/the-paradigm-shift-led-by-cdk4-6-inhibitors-in-breast-cancer/9255627-1-eng-GB/the-paradigm-shift-led-by-cdk4-6-inhibitors-in-breast-cancer_i770.jpg)
The paradigm shift led by CDK4/6 inhibitors in breast cancer
The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.
![GI_PP_19.09_All speakers](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/gi_pp_19.09_all-speakers/9259713-1-eng-GB/gi_pp_19.09_all-speakers_i770.jpg)
Does perioperative chemotherapy improve outcomes in PDAC? Evidence is not yet conclusive
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
![Public 3](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-3/9144006-1-eng-GB/public-3_i770.jpg)
Positive early clinical results for amivantamab plus lazertinib in NSCLC
Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib
![Public 1](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-1/9144114-1-eng-GB/public-1_i770.jpg)
Preclinical research offers promise of new CDK4/6 inhibitors
Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models
![Delegates walking 3](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/delegates-walking-3/9143766-1-eng-GB/delegates-walking-3_i770.png)
Switch maintenance with darolutamide shows promise in previously treated mCRPC
Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study
![GU discussion 19.09_ESMO 2021](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/gu-discussion-19.09_esmo-2021/9261447-2-eng-GB/gu-discussion-19.09_esmo-2021_i770.png)
Possible changes in the standard of care for metastatic and non-metastatic prostate cancer
Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer
![AC PJ chairing Presidential Symposium 2](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/ac-pj-chairing-presidential-symposium-2/9260841-2-eng-GB/ac-pj-chairing-presidential-symposium-2_i770.png)
KRAS G12C inhibition shows potential for the improved management of advanced CRC
Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials
![Breast_PP_19.09](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/breast_pp_19.09/9260061-1-eng-GB/breast_pp_19.09_i770.jpg)
Longer survival benefit with pembrolizumab plus chemotherapy in TNBC
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease
![LBA30_PAPACHRISTOFILOU](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/lba30_papachristofilou/9259941-1-eng-GB/lba30_papachristofilou_i770.jpg)
De-escalated treatment improves the management of stage IIA/B seminoma
Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy